公开(公告)号：US20130266568A1

公开(公告)日：2013-10-10

申请号：US13773013

申请日：2013-02-21

申请人： Roche Glycart AG

发明人： ULRICH BRINKMANN ,  REBECCA CROASDALE ,  SILKE METZ ,  JUERGEN MICHAEL SCHANZER ,  CLAUDIO SUSTMANN ,  PABLO UMANA

IPC分类号： C07K16/46

CPC分类号： C07K16/468 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/624 ,  C07K2317/64 ,  C07K2317/92 ,  C07K2319/00

摘要： The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies.

摘要翻译： 本发明涉及双特异性抗体，其中对两种抗原之一的结合亲和力降低，并且其可被肿瘤或炎症特异性蛋白酶激活，以及这种双特异性抗体的制备和用途。

公开(公告)号：US20160145354A1

公开(公告)日：2016-05-26

申请号：US14835439

申请日：2015-08-25

申请人： Roche Glycart AG

发明人： MARINA BACAC ,  PETER BRUENKER ,  CHRISTIANE JAEGER ,  CHRISTIAN KLEIN ,  EKKEHARD MOESSNER ,  PABLO UMANA ,  TINA WEINZIERL

IPC分类号： C07K16/46 ,  C07K16/30 ,  C07K16/32 ,  C07K16/28

CPC分类号： C07K16/468 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3053 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2317/66 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00

摘要： The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

公开(公告)号：US20140065134A1

公开(公告)日：2014-03-06

申请号：US13829409

申请日：2013-03-14

申请人： ROCHE GLYCART AG

发明人： CHARLES DUMONTET ,  THOMAS FRIESS ,  FRANK HERTING ,  CHRISTIAN KLEIN ,  PABLO UMANA

IPC分类号： A61K39/395 ,  A61K31/573 ,  A61K31/704 ,  A61K31/675 ,  A61K31/475

CPC分类号： A61K39/39558 ,  A61K31/475 ,  A61K31/573 ,  A61K31/664 ,  A61K31/675 ,  A61K31/704 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/732 ,  A61K2300/00

摘要： The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.

摘要翻译： 本发明涉及药物组合物，其包含：（A）具有增加的抗体依赖性细胞毒性（ADCC）的II型抗CD20抗体; 和（B）选自环磷酰胺，长春新碱和多柔比星的化疗剂。 本发明还涉及一种用于治疗表达CD20的癌症的方法，包括对需要这种治疗的患者施用（i）有效的第一量的具有增加的抗体依赖性细胞毒性的II型抗CD20抗体; 和（ii）有效的第二量的一种或多种选自环磷酰胺，长春新碱和多柔比星的化学治疗剂。

公开(公告)号：US20160000912A1

公开(公告)日：2016-01-07

申请号：US14305996

申请日：2014-06-16

申请人： Roche Glycart AG

发明人： GEORG FERTIG ,  THOMAS FRIESS ,  CHRISTIAN KLEIN ,  PABLO UMANA

IPC分类号： A61K39/395 ,  A61K47/00 ,  A61K31/69

CPC分类号： A61K39/39558 ,  A61K31/69 ,  A61K47/00 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  A61K2300/00

摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor.

摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是表达CD20的癌症的II型抗-CD20抗体和蛋白酶体抑制剂的组合疗法。 本发明的一个方面是包含II型抗CD20抗体和蛋白酶体抑制剂的组合物。 本发明的另一方面是包含II型抗CD20抗体和蛋白酶体抑制剂的试剂盒。 本发明的另一方面是治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同施用II型抗CD20抗体和蛋白酶体抑制剂。

公开(公告)号：US20160000911A1

公开(公告)日：2016-01-07

申请号：US14297478

申请日：2014-06-05

申请人： ROCHE GLYCART AG

发明人： CHARLES DUMONTET ,  THOMAS FRIESS ,  FRANK HERTING ,  CHRISTIAN KLEIN ,  PABLO UMANA

IPC分类号： A61K39/395 ,  A61K31/573 ,  A61K31/704 ,  A61K31/664 ,  A61K31/475

CPC分类号： A61K39/39558 ,  A61K31/475 ,  A61K31/573 ,  A61K31/664 ,  A61K31/675 ,  A61K31/704 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/732 ,  A61K2300/00

摘要： The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.

摘要翻译： 本发明涉及药物组合物，其包含：（A）具有增加的抗体依赖性细胞毒性（ADCC）的II型抗CD20抗体; 和（B）选自环磷酰胺，长春新碱和多柔比星的化疗剂。 本发明还涉及一种用于治疗表达CD20的癌症的方法，包括对需要这种治疗的患者施用（i）有效的第一量的具有增加的抗体依赖性细胞毒性的II型抗CD20抗体; 和（ii）有效的第二量的一种或多种选自环磷酰胺，长春新碱和多柔比星的化学治疗剂。

公开(公告)号：US20140294807A1

公开(公告)日：2014-10-02

申请号：US14067799

申请日：2013-10-30

申请人： ROCHE GLYCART AG

发明人： THOMAS FRIESS ,  CHRISTIAN KLEIN ,  PABLO UMANA

IPC分类号： A61K39/395

CPC分类号： A61K39/39558 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56

摘要： The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody.

摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是CD20表达癌症的患者的I型抗CD20抗体和II型抗-CD20抗体的组合疗法。 本发明的一个方面是包含I型抗CD20抗体和II型抗-CD20抗体的组合物。 本发明的另一方面是包含I型抗CD20抗体和II型抗CD20抗体的试剂盒。 本发明的另一方面是用于治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同给予I型抗CD20抗体和II型抗-CD20抗体。